-
1.发明申请MUTATIONS IN THE LNK GENE IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS AND OTHER HEMATOLYMPHOID MALIGNANCIES 有权LNK基因突变患者与非嗜铬细胞性淋巴瘤和其他HEMATOLYMPHOID恶性肿瘤公开(公告)号：US20120046233A1
公开(公告)日：2012-02-23
申请号：US13005455
申请日：2011-01-12
IPC分类号： A61K38/02 , A61P35/00 , C12Q1/02 , C12Q1/68 , G01N33/566
CPC分类号： C12Q1/6886 , C12Q2600/136 , C12Q2600/156
摘要： Aspects of the present invention include methods, compositions and kits for classifying a subject as having or being predisposed to a hematolymphoid neoplasm or malignancy if they harbor a mutation in the LNK gene. Aspects of the present invention also include screening for candidate agents for treating LNK mutation-based hematolymphoid neoplasms or malignancies in cell-based and cell free assays as well as therapeutic compositions for treating a LNK-mutant based hematolymphoid disorder. Also provided are compositions, systems, kits and computer program products that find use in practicing the subject methods.
摘要翻译： 本发明的方面包括用于将受试者分类为具有或倾向于血淋巴肿瘤或恶性肿瘤的方法，组合物和试剂盒，如果它们在LNK基因中存在突变。 本发明的方面还包括在基于细胞和无细胞测定中筛选用于治疗基于LNK突变的血液淋巴样肿瘤或恶性肿瘤的候选药物以及用于治疗基于LNK突变体的血淋巴病症的治疗组合物。 还提供了用于实践主题方法的组合物，系统，试剂盒和计算机程序产品。
-
2.发明授权Mutations in the LNK gene in patients with myeloproliferative neoplasms and other hematolymphoid malignancies 有权骨髓增生性肿瘤和其他血液淋巴恶性肿瘤患者LNK基因突变公开(公告)号：US08945846B2
公开(公告)日：2015-02-03
申请号：US13005455
申请日：2011-01-12
CPC分类号： C12Q1/6886 , C12Q2600/136 , C12Q2600/156
摘要： Aspects of the present invention include methods, compositions and kits for classifying a subject as having or being predisposed to a hematolymphoid neoplasm or malignancy if they harbor a mutation in the LNK gene. Aspects of the present invention also include screening for candidate agents for treating LNK mutation-based hematolymphoid neoplasms or malignancies in cell-based and cell free assays as well as therapeutic compositions for treating a LNK-mutant based hematolymphoid disorder. Also provided are compositions, systems, kits and computer program products that find use in practicing the subject methods.
摘要翻译： 本发明的方面包括用于将受试者分类为具有或倾向于血淋巴肿瘤或恶性肿瘤的方法，组合物和试剂盒，如果它们在LNK基因中存在突变。 本发明的方面还包括在基于细胞和无细胞测定中筛选用于治疗基于LNK突变的血液淋巴样肿瘤或恶性肿瘤的候选药物以及用于治疗基于LNK突变体的血淋巴病症的治疗组合物。 还提供了用于实践主题方法的组合物，系统，试剂盒和计算机程序产品。
-
搜索结果
2 条记录 (耗时 0.024 秒)
